Cargando…

PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients

Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of the nuclear hormone receptor superfamily, have been identified as key metabolic regulators in the liver, skeletal muscle, and adipose tissue, among others. As a leading cause of liver disease worldwide, non...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lange, Naomi F., Graf, Vanessa, Caussy, Cyrielle, Dufour, Jean-François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028563/ https://www.ncbi.nlm.nih.gov/pubmed/35457120 http://dx.doi.org/10.3390/ijms23084305

Ejemplares similares

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
por: Dufour, Jean-François, et al.
Publicado: (2020)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Obésité et infection par la COVID-19 : une liaison dangereuse
por: Caussy, Cyrielle
Publicado: (2021)

Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two‐dimensional shear wave elastography in non‐alcoholic fatty liver disease
por: Mendoza, Yuly P., et al.
Publicado: (2021)

Non-alcoholic fatty liver disease and diabetes
por: Hazlehurst, Jonathan M., et al.
Publicado: (2016)

The effects of S-nitrosylation-induced PPARγ/SFRP5 pathway inhibition on the conversion of non-alcoholic fatty liver to non-alcoholic steatohepatitis
por: Wang, Hongyun, et al.
Publicado: (2021)

Autophagy and Non-Alcoholic Fatty Liver Disease
por: Lavallard, Vanessa J., et al.
Publicado: (2014)

Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology
por: Memaj, Plator, et al.
Publicado: (2022)

Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus
por: Padda, Jaskamal, et al.
Publicado: (2021)

Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
por: Snyder, Heather S., et al.
Publicado: (2018)

Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease
por: Zarei, Mohammad, et al.
Publicado: (2017)

Non-alcoholic fatty liver disease and diabetic retinopathy: Is there an association?
por: Jacob, Mathew, et al.
Publicado: (2023)

Smad3 Mediates Diabetic Dyslipidemia and Fatty Liver in db/db Mice by Targeting PPARδ
por: He, Huijun, et al.
Publicado: (2023)

Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort
por: Tang, Kuo-Tung, et al.
Publicado: (2020)

Is there an effective therapy available for non-alcoholic fatty liver disease?
por: Di Maso, Vittorio, et al.
Publicado: (2009)

Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver
por: Foroughi, Mehdi, et al.
Publicado: (2016)

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease
por: Kim, Hyejin, et al.
Publicado: (2023)

Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients()
por: Goh, George Boon-Bee, et al.
Publicado: (2014)

Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease
por: Goossens, Nicolas, et al.
Publicado: (2017)

Non-alcoholic fatty liver disease
por: Sattar, Naveed, et al.
Publicado: (2014)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
por: Cainelli, Francesca, et al.
Publicado: (2020)

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
por: Hattori, Sachiko, et al.
Publicado: (2021)

Managing non‐alcoholic fatty liver disease in diabetes: Challenges and opportunities
por: Lee, Chi‐Ho, et al.
Publicado: (2016)

Lean non-alcoholic fatty liver disease: do not forget diabetes
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease, diabetes medications and blood pressure
por: Ilias, Ioannis, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist?
por: Khandelwal, Reshu, et al.
Publicado: (2021)

Non‐alcoholic fatty liver disease and type 2 diabetes: An update
por: Lee, Chi‐H, et al.
Publicado: (2022)

Autophagy in non-alcoholic fatty liver disease and alcoholic liver disease()
por: Khambu, Bilon, et al.
Publicado: (2018)

Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease: Is the Liver Another Target?
por: Mirrakhimov, Aibek E., et al.
Publicado: (2012)

Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases
por: Raff, Evan J., et al.
Publicado: (2015)

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
por: Eshraghian, Ahad
Publicado: (2017)

Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?
por: Chandrasekharan, Karthik, et al.
Publicado: (2020)

Benefits of the Therapy With Abexol in Patients With Non-Alcoholic Fatty Liver Disease
por: Fernandez-Travieso, Julio Cesar, et al.
Publicado: (2020)

Danshao Shugan Granule therapy for non-alcoholic fatty liver disease
por: Wang, Hui, et al.
Publicado: (2022)

Therapies for non-alcoholic fatty liver disease: A 2022 update
por: Shen, Katie, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease and liver secretome
por: Khan, Muhammad Sohaib, et al.
Publicado: (2022)

Dendrobium mixture ameliorates type 2 diabetes mellitus with non-alcoholic fatty liver disease through PPAR gamma: An integrated study of bioinformatics analysis and experimental verification
por: Zhuang, Shuting, et al.
Publicado: (2023)

Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar
por: Grobbee, Esmée J., et al.
Publicado: (2022)

Update on Pparγ and Nonalcoholic Fatty Liver Disease
por: Ables, Gene P.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4bvh4sagvmh7qh8efi9jrd2lt3